ID

26106

Description

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Study conclusion

Mots-clés

Versions (4)
  1. 09/10/2017 09/10/2017 -
  2. 13/10/2017 13/10/2017 -
  3. 23/10/2017 23/10/2017 -
  4. 11/01/2018 11/01/2018 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

9 octobre 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Study conclusion GSK study Chronic Coronary Heart Disease NCT00799903

Anglais

Study conclusion GSK study Chronic Coronary Heart Disease NCT00799903

1 Formulaires  
Study conclusion
Description

Study conclusion

1. Date of subject completion or withdrawal
Description

Date of subject completion or withdrawal

Type de données

date

2. Was the subject withdrawn from the study before study reached GSK target number of primary clinical endpoints?
Description

subject withdrawal

Type de données

text

3. Primary reason for withdrawal
Description

Item is not required

Type de données

integer

If lost to Follow-up, provide comment
Description

Pre-defined sub-reasons are optional. The following primary reasons are optional : 2, 4 and 7. Pre-defined sub-reasons may/should be moved under appropriate primary reasons. See specific note for Group DSRS8.

Type de données

text

If subject withdrew consent, provide comment
Description

Pre-defined sub-reasons are optional. The following primary reasons are optional : 2, 4 and 7. Pre-defined sub-reasons may/should be moved under appropriate primary reasons. See specific note for Group DSRS8.

Type de données

text

If investigator site closed, provide comment
Description

Pre-defined sub-reasons are optional. The following primary reasons are optional : 2, 4 and 7. Pre-defined sub-reasons may/should be moved under appropriate primary reasons. See specific note for Group DSRS8.

Type de données

text

4. For Data Managers or Monitors only: Tick or untick this box to require the investigator to re-sign the case book
Description

By ticking or unticking this box you are evoking a change to this form that will invalidate the original signature and will revert the form back to an unsigned state. This should be done when significant changes (e.g. those that require medical opinion or other significant situations) occur after the original signature. If the box is already ticked upon arrival on this form, unticking and submitting it accomplishes the same task as ticking and submitting it; that is, the signature will be invalidated in both instances. [hidden]. Item is not required.

Type de données

integer

5. Q1
Description

[hidden] Item is not required

Type de données

boolean

6. Q2
Description

[hidden] Item is not required

Type de données

text

Retour au début de la page

Similar models

Study conclusion GSK study Chronic Coronary Heart Disease NCT00799903

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Study conclusion
Date of subject completion or withdrawal
Item
1. Date of subject completion or withdrawal
date
Item
2. Was the subject withdrawn from the study before study reached GSK target number of primary clinical endpoints?
text
subject withdrawal
Code List
2. Was the subject withdrawn from the study before study reached GSK target number of primary clinical endpoints?
CL Item
No (N)
CL Item
Yes, complete primary reason for withdrawal (Y)
Item
3. Primary reason for withdrawal
integer
Primary reason for withdrawal
Code List
3. Primary reason for withdrawal
CL Item
Study closed/terminated (5)
CL Item
Lost to Follow-up (6)
CL Item
Withdrew consent (8)
CL Item
Investigator site closed (12)
lost to Follow-up comment
Item
If lost to Follow-up, provide comment
text
withdrawal of consent comment
Item
If subject withdrew consent, provide comment
text
investigator site closed comment
Item
If investigator site closed, provide comment
text
Item
4. For Data Managers or Monitors only: Tick or untick this box to require the investigator to re-sign the case book
integer
e-sign the case book
Code List
4. For Data Managers or Monitors only: Tick or untick this box to require the investigator to re-sign the case book
CL Item
1 (1)
Q1
Item
5. Q1
boolean
Item
6. Q2
text
Q2
Code List
6. Q2
CL Item
PF_SC_LOST (PF_SC_LOST)
CL Item
[?] PF_SC_DEATH ([?] PF_SC_DEATH)
CL Item
[?] PF_SC_SPONSORDECISION ([?] PF_SC_SPONSORDECISION)
CL Item
PF_SC_PHYSICIANDECISION (PF_SC_PHYSICIANDECISION)
CL Item
PF_SC_PATIENTDECISION (PF_SC_PATIENTDECISION)
CL Item
PF_SC_AE (PF_SC_AE)
CL Item
PF_SC_ALE (PF_SC_ALE)
CL Item
PF_SC_CRITERIA (PF_SC_CRITERIA)
CL Item
PF_SC_OTHER (PF_SC_OTHER)
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial